-
A Promising but Controversial New Depression Treatment Is Now More Accessible in Vermont
A primary care doctor at the University of Vermont Health Network will soon start treating depression with a mind-altering drug that’s shown promise in helping people who don’t respond to traditional medicine.
The medication — known as esketamine and sold by Johnson & Johnson under the brand name Spravato — is chemically similar to ketamine, a substance that’s been used in medical settings as an anesthetic, on the streets as a party drug and, more recently, as an off-label treatment for mood disorders.
-
Andrew Tripp Is an All-Star Union Organizer — and a Kick-Ass Cross-Country Coach, Too
Referring to the final turn, the U-32 coach said, “It’s going to hurt very badly, but only for 15 seconds, OK?”
Normally, Tripp, who is 52, would have been running with them. But he had a cold, so he reverted to his race-day role of sideline encouragement, which he delivers in an emotional register that will stay imprinted in their amygdalae into adulthood.
“Amy, let’s go, girl! Faster!”
Youtube